Characteristics Identified for Risk of Very Severe irAEs With Immune Checkpoint Inhibitor Therapy
Very severe immune-related adverse events on immune checkpoint inhibitor therapy occur earlier than less severe ones appear to and may have predictors.
Immune Checkpoint Inhibitors
Immune Checkpoint Inhibitor Therapy Tied to Cardiac Event Risk
Increased risks persist beyond six months for patients with lung cancer receiving PD1i and with malignant melanoma receiving CTLA-4i.
Vitamin D May Reduce Immune Checkpoint Inhibitor–Related Colitis
Vitamin D may be used to reduce the risk of immune checkpoint inhibitor-related colitis, as well as ulcerative colitis and graft-vs-host disease.
Vitamin D May Cut Colitis Risk for Immune Checkpoint Inhibitors
Odds of developing ICI colitis significantly reduced with vitamin D use in patients with melanoma.
Approach Immune Checkpoint Inhibitor Rechallenge Cautiously After Initial Immune-Related Adverse Events
Researchers suggest appropriate monitoring and use of standard treatment algorithms to identify and treat toxic effects after a rechallenge after irAEs in patients receiving ICI therapy.
Sequence of Immunotherapy, Targeted Therapy, Radiation Therapy Influences Overall Survival in Melanoma Brain Metastases
Retrospective study investigated the effect sequence has on overall survival in patients with melanoma brain metastases treated with a combination of SRS, WBRT, immunotherapy, or targeted therapy.
Immune Checkpoint Inhibitor Therapy May Affect Thyroid Function
A review of medical records revealed that thyroid function may be affected by immune checkpoint inhibitor therapy, and these patients should undergo thyroid function tests, especially during the first 8 weeks of therapy.
HPV Vaccination and Anti-programmed Cell Death 1 Inhibition Improve Survival in Patients With Invasive HPV-16
In this study, researchers sought to determine if use of a tumor specific vaccine would improve the efficacy of PD-1 immune checkpoint inhibition in patients with incurable HPV-16 cancer.
Immunotherapy Tolerable for Cancer Patients With Rheumatologic Disease
In this retrospective study, researchers sought to determine if cancer patients with rheumatologic disease would be able to tolerate cancer treatment with immune checkpoint inhibitors or if these agents would induce a rheumatologic disease flare.
Survival Predictors in Ovarian Cancer and Current Immunotherapeutic Strategies
Researchers have found 3 major predictors for survival: tumor infiltrating leukocytes (TIL), programmed death-ligand 1 (PD-L1) expression, and mutational burden.
- Loading...
Loading...
Next post in Ovarian Cancer
Loading... 
Loading...